UNSPSC 51334508: Loxapine succinate

This classification denotes an antipsychotic agent with the molecular formula C18H18ClN3O.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X59SG0MRYU, chemically known as 1,4-butanedioic acid (succinic acid) but more generally known as loxapine succinate, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Loxapine succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02977MIG.

Most nations, for tariff and trade purposes, schedule loxapine succinate under HS 29349990 and SITC 51579. As of Q4 2014, LOXAPINE SUCCINATE remains US FDA's Preferred Term for this commodity. Loxapine succinate bears US NLM identifiers UMLS ID C0024057 and NCI Concept Code C47590. SMILES: CN1CCN(CC1)C2=NC3CCCCC3OC4C2CC(CC4)CL.C(CC(=O)O)C(=O)O.

UNSPSC 51334508 Loxapine succinate is a Commodity code that captures pharmaceutical products procured by state and local health authorities, though recent opportunities tagged under this code show little activity specifically for loxapine itself. The recent solicitations reveal a broader pattern: state and local buyers are sourcing naloxone, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing mechanisms, typically as part of community health initiatives, pharmacy benefit programs, or standing supply agreements across multiple jurisdictions. State health departments, county health systems, and multistate cooperative purchasing alliances drive procurement under this family, with Seminole County, Florida and the Texas Health and Human Services Commission and Minnesota Department of Administration appearing as representative issuing bodies.

Solicitation activity concentrates in Florida, Texas, and Minnesota, with cooperative purchasing extending across participating states including Oregon. Recent representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas HHS Commission's Request for Information HHS0017013 (posted April 3, 2026) gathering vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities with authorized wholesaler distribution beginning July 1, 2026. The MMCAP contract requires FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and pricing submission in flat price or net price formats, with awards made on a two-year initial term plus optional extensions.